Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Antibody Stratified Therapy with Radiotherapy for Early-Stage NKTCL
NCT07380984Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2026
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
Phase 2, open-label trial in Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Progression-Free Survival Rate at 2 years. Started Mar 2026; status: recruiting.
02
Conditions
Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT)
Beyond the preview
Go deeper on NCT07380984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07380984.